CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD5 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.

NCT Number	NCT07022964
Lead Sponsor	Beijing GoBroad Hospital Collaborators: Ruijin Hospital, Shanghai Liquan Hospital
Conditions	T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
Enrollment	36 participants
Start Date	2025-06-01
Primary Completion	2026-06-01 (estimated)
Study Completion	2028-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-06-15